← Leap Therapeutics, Inc. (LPTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Leap Therapeutics, Inc. (LPTX)
Pharmaceutical Preparations · market cap $25M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-01-31 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Leap Therapeutics (LPTX) is a clinical-stage pharmaceutical company with a market cap of approximately $25M and a stock price near $0.44. Its lead asset, DKN-01, is in Phase 2 development for colorectal cancer, with a second program pairing DKN-01 with paclitaxel in Phase 2 for endometrial cancer. The company carries no analyst coverage, no upcoming catalysts on the calendar, and significant historical cash burn, raising acute questions about financial sustainability.
The catalyst path
- 2027-01-31 (est.)Phase 2 · DKN-01imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| DKN-01 | Phase 2 | Colorectal Cancer |
| 300mg DKN-01 | Phase 2 | Endometrial Cancer |
Price & technical context
3-month
+29.1%
6-month
+9.4%
12-month
-87.4%
52-wk range
$0.24–$3.48
vs 50-day MA
-2.0%
vs 200-day MA
+10.7%
Realized vol
172.1%
Max drawdown
-94.9%
Daily closes through 2025-11-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LPTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.